P1 is purely safety - don't need that because we can use Alzheimer's. We should go to P2/3, testing of dosages and monitoring effect, then progress relatively quickly to P3.
MJFF funded the preclinical and it was done under their supervision.
Adding two scientific advisory members to the Anavex team that are also on the MJFF BOD seems significant to me.
Market Data 
Markets 
AI
